










HIV PREVENTION RESEARCH: A COMPREHENSIVE TIMELINE OF EFFICACY TRIALS*

2007	2008	2009	2010	2011	2013
<p>FHI Phase III trial of the vaginal microbicide Cellulose Sulfate gel for the prevention of HIV infection in women</p> <p>Trial stopped early—January 2007 Results announced July 2007</p>	<p>Phase III trial of the vaginal microbicide Carraguard for the prevention of HIV infection in women</p> <p>Results anticipated in November</p>	<p>Phase III trial of a prime-boost (ALVAC-AIDSVAX) combination preventive HIV vaccine</p>	<p>Large-scale trial of a once-daily dose of Truvada® to prevent HIV infection in high-risk HIV-negative men who have sex with men</p>	<p>Phase III trial of community mobilization, mobile testing, same-day results, and post-test support for HIV</p>	<p>Phase III trial to determine the effectiveness of two antiretroviral treatment strategies in preventing the sexual transmission of HIV in HIV-serodiscordant couples</p>
<p>CONRAD Phase III trial of the vaginal microbicide Cellulose Sulfate gel for the prevention of HIV infection in women</p> <p>Trial stopped early—January 2007 Results announced July 2007</p>	<p>Phase III trial of acyclovir for the reduction of HIV infection in high-risk, HIV-negative, HSV-2 seropositive individuals</p>	<p>Phase II/IIb trial of the vaginal microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the prevention of HIV infection in women</p>	<p>Phase II trial of the vaginal microbicide tenofovir gel for the prevention of HIV infection in women</p>		
<p>Study of different risk-reduction interventions for HIV vaccine trials (Project UNITY)</p>	<p>Phase III trial of the vaginal microbicide PRO 2000 for the prevention of HIV infection in women</p>	<p>Phase III trial of the vaginal microbicide PRO 2000 for the prevention of HIV infection in women</p>			
<p>Phase III trial of the female diaphragm to prevent HIV infection in women</p> <p>Results announced July 2007</p>	<p>Large-scale trial of a once-daily dose of tenofovir to prevent HIV infection in injecting drug users</p>	<p>Phase II trial to test the clinical and behavioral safety of a once-daily dose of tenofovir among HIV-negative men who have sex with men</p>			
<p>Test-of-concept trial of Merck's adenovirus preventive HIV vaccine candidate (Step study)</p> <p>Trial halted immunizations, September 2007. Follow-up and data collection continue.</p>	<p>Phase III trial of HSV-2 suppression in serodiscordant couples</p>	<p>Large-scale trial of a once-daily dose of Truvada® to prevent HIV infection in heterosexual men and women</p>			
<p>Test-of-concept trial of Merck's adenovirus preventive HIV vaccine candidate (Phambili)</p> <p>Trial halted enrollment and immunizations, September 2007. Follow-up and data collection continue.</p>	<p>Large-scale trial to evaluate the safety of male circumcision and its potential protective effect for HIV-negative female partners of HIV-positive circumcised males</p> <p>Trial stopped enrollment and surgeries in December 2006. Follow-up and data collection continue.</p>				

 VACCINE	 CERVICAL BARRIER METHOD
 PRE-EXPOSURE PROPHYLAXIS (PrEP)	 PARTNER TREATMENT
 HSV-TREATMENT/SUPPRESSION	 BEHAVIORAL
 MICROBICIDE	 TRIAL COMPLETED OR STOPPED
 MALE CIRCUMCISION	

To view this timeline online with trial details please visit www.avac.org/timeline-website/

* The trial end-dates listed in this table are estimates. Due to the nature of clinical trials the actual dates may change. AVAC will continue to monitor the trials' progress and will update the timeline accordingly. If you have any questions regarding the information presented here please email avac@avac.org.